April 23rd, 2021

View in Browser
Q1 2021

Pulse On Progress Newsletter

Table of Contents


Transcelerate aspires for a future state where research and development is faster, more efficient and harnesses all the available information. We invision this happening three ways:

  1. Full participation across all stakeholders—clinical trial sponsors, sites, investigators, patients and their healthcare providers.
  2. Information is fully used to improve the overall quality, design and development process. We protect patients through shared, proactive safety science.
  3. Improving the execution of research and development through greater harmonization with the potential to conduct collaborative trials.

Newest Resources and Company Milestones

  • BioCelerate’s SEND Harmonization Initiative published its second manuscript, co-authored in collaboration with the FDA as part of its Public-Private Partnership, in Chemical Research in Toxicology’s Computational Toxicology Special Edition. The article, "Leveraging the Value of CDISC SEND Datasets for Cross-Study Analysis:
    Incidence of Microscopic Findings in Control Animals
    " highlights the potential of SEND datasets for cross-study analysis and proposes solutions to address the challenges of doing so currently.
  • SCOPE 2021 finished on March 4 after three days filled with informative sessions related to the R&D and pharma industry. TransCelerate had the opportunity to present 10 sessions over the course of the conference covering many topics related to our solutions and initiatives. To read the in-depth recap of our sessions, click here.
  • We welcomed Andrew Hudson (Roche), who is the new Chair for the TransCelerate Pharmacovigilance (PV) Steering Committee. He will be taking over for Paul Chang (Johnson & Johnson), who we would like to thank for his dedication as Chair over the last two years. The innovative and synergetic energy he has brought to the committee during his time within TransCelerate's leadership has been appreciated.

Pulse On Progress Updates

Patient & Site Experience

Objective: Improve the patient and site experience by decreasing burden, enabling a better-informed patient and improving clinical research awareness, participation & engagement.

Enhance Sponsor Efficiencies

Objective: Facilitate the advancement of innovative healthcare and clinical research through improved technologies, advanced data collection systems and simplified processes.

Enhance Drug Safety

Objective: Facilitate solutions that address a common set of challenges in drug safety surveillance such as engaging the public, collaborating with regulators, incorporating data and analytics, developing model approaches, and assessing the impact of efforts.


Blog Updates & The Spotlight

Check Out Our Blog




We spoke with Kristof Huysentruyt (UCB) on how machine learning, natural language processing, and artificial intelligence (AI) are becoming more prevalent across the biopharmaceutical industry as well as the challenges the industry is facing in validating this technology.


Mark Your Calendars

TransCelerate leaders and Member Companies are invited to participate and present at many biopharmaceutical research industry conferences and meetings across the globe to provide a perspective on industry challenges and clinical trial issues. Take a peek at a few places we will be presenting early next year. For detailed information on speaker presentations, visit the events page on the TransCelerate website.

April 7-9, 2021

Pharma: Clinical

Virtual Attendance

April 7-9, 2021

Patients as Partners U.S.

Virtual Attendance

April 20-22, 2021

SCRS European Site Solutions Summit 2021

Virtual Attendance

May 20-23, 2021

DIA China

Suzhou, China

May 24-27, 2021

Pharma SUG

Virtual Attendance

June 7-9, 2021

ARCS Annual Meeting

Sydney, Australia

June 14-18, 2021

PHUSE Connect US 2021

Virtual Attendance

June 27 – July 1, 2021

DIA Global Annual Meeting

June 27 – July 1, 2021

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
TransCelerate BioPharma Inc. · 1001 Conshohocken State Road · STE 1-655 · Conshohocken, PA 19428 · USA